About
Technology
Issues
FAQ
Links
Official Page
Re‐treatment with radium‐223: 2‐year follow‐up from an international, open‐label, phase 1/2 study in patients with castration‐resistant prostate cancer and bone metastases
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.